- Home
- APXT vs CATX Comparison
APXT vs CATX Comparison
Compare APXT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.00
HOLD
Current Price
$3.79
Company Overview
Basic Information| Metric | APXT | CATX |
|---|---|---|
| Founded | 2025 | 1983 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.3M | 497.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | APXT | CATX |
|---|---|---|
| Price | $10.00 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 124.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.96 |
| 52 Week High | $10.01 | $6.16 |
Technical Indicators
Market Signals| Indicator | APXT | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 42.09 |
| Support Level | N/A | $3.24 |
| Resistance Level | $10.00 | $3.89 |
| Average True Range (ATR) | 0.01 | 0.31 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 100.00 | 21.60 |
Price Performance
Historical Comparison APXT
CATX
About APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.